Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Humacyte (NASDAQ:HUMA) and maintained a $15 price target.
August 12, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Humacyte and maintained a $15 price target.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100